Jafron Biomedical Co Stock Fundamentals
| 300529 Stock | 25.74 0.67 2.67% |
Jafron Biomedical Co fundamentals help investors to digest information that contributes to Jafron Biomedical's financial success or failures. It also enables traders to predict the movement of Jafron Stock. The fundamental analysis module provides a way to measure Jafron Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jafron Biomedical stock.
At present, Jafron Biomedical's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 296.3 M, whereas Selling General Administrative is forecasted to decline to about 312.9 M. Jafron | Select Account or Indicator |
Jafron Biomedical Co Company Current Valuation Analysis
Jafron Biomedical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Jafron Biomedical Current Valuation | 19.46 B |
Most of Jafron Biomedical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jafron Biomedical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Jafron Biomedical Co has a Current Valuation of 19.46 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.
Jafron Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jafron Biomedical's current stock value. Our valuation model uses many indicators to compare Jafron Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jafron Biomedical competition to find correlations between indicators driving Jafron Biomedical's intrinsic value. More Info.Jafron Biomedical Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Jafron Biomedical Co is roughly 2.35 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jafron Biomedical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jafron Biomedical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jafron Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jafron Biomedical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jafron Biomedical could also be used in its relative valuation, which is a method of valuing Jafron Biomedical by comparing valuation metrics of similar companies.Jafron Biomedical is currently under evaluation in current valuation category among its peers.
Jafron Fundamentals
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 19.46 B | ||||
| Shares Outstanding | 798.6 M | ||||
| Shares Owned By Insiders | 51.06 % | ||||
| Shares Owned By Institutions | 13.19 % | ||||
| Price To Book | 6.25 X | ||||
| Price To Sales | 7.81 X | ||||
| Revenue | 1.92 B | ||||
| Gross Profit | 2.12 B | ||||
| EBITDA | 1.04 B | ||||
| Net Income | 436.49 M | ||||
| Total Debt | 261.83 M | ||||
| Book Value Per Share | 4.25 X | ||||
| Cash Flow From Operations | 916.74 M | ||||
| Earnings Per Share | 1.00 X | ||||
| Target Price | 38.21 | ||||
| Number Of Employees | 2.41 K | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 20.56 B | ||||
| Total Asset | 5.54 B | ||||
| Retained Earnings | 2 B | ||||
| Working Capital | 2.48 B | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 5.54 B | ||||
| Last Dividend Paid | 0.4 |
About Jafron Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jafron Biomedical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jafron Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jafron Biomedical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.2 B | 1.2 B | |
| Cost Of Revenue | 441.6 M | 463.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Jafron Stock
Jafron Biomedical financial ratios help investors to determine whether Jafron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jafron with respect to the benefits of owning Jafron Biomedical security.